Caterpillar Inc. bolsters Southern Community study with $1 million gift

November 18, 2003

NASHVILLE, Tenn. -- The Southern Community Cohort Study (SCCS), the largest population-based health study of African-Americans ever conducted, has received a critical infusion of support from Caterpillar Inc., which has pledged $1 million to the historic initiative.

A $22 million, five-year federal grant to fund the study is significant but fell $6 million short of the initial proposal. The Vanderbilt-Ingram Cancer Center has committed to raise the shortfall through private philanthropy.

The pledge from Caterpillar, the world's largest manufacturer of construction and mining equipment, natural gas and diesel engines and industrial gas turbines, is the largest private gift thus far. The study is an innovative collaboration among Vanderbilt, Meharry Medical College, the International Epidemiology Institute and federally funded community health centers (CHCs) throughout the Southeast.

"This is an ambitious project of national and international importance," said Dr. Harry R. Jacobson, vice chancellor for Health Affairs at Vanderbilt. "We must meet the challenge of ensuring that advances in medicine are shared equally, regardless of race, geography or economic status. This generous gift from Caterpillar goes a long way toward ensuring that the full promise of this landmark study will be realized."

The study will provide critical information to help understand - and ultimately address - why African-Americans and residents of the Southeast are at greater risk of developing and dying from cancer than other groups. While the study's initial focus is on cancer, the cohort will provide invaluable information for the study of other significant health problems, including diabetes, heart disease and stroke, all of which also disproportionately affect African-Americans and Southerners.

"When it comes to social responsibility, Caterpillar makes betterment of the world a formal part of its corporate strategy," said Vanderbilt Chancellor E. Gordon Gee. "This pledge is an outstanding illustration of that commitment, and provides an important infusion of support for the Vanderbilt-Ingram Cancer Center's program in epidemiology.

"I also want to thank Caterpillar for its decade of support for Vanderbilt and the Owen School and to express my hopes that Caterpillar and Vanderbilt will find many creative ways to work together in the years to come."

"Caterpillar's leadership has been impressed with the ambitious scope of the SCCS and with its ultimate goal of eliminating racial, ethnic and regional disparities in cancer and other diseases," said Douglas R. Oberhelman, group president of Peoria, Ill.-based Caterpillar Inc. "In the discussions that we had with the lead investigators, it became clear that they have an extraordinary vision," Oberhelman said. "Caterpillar is a company that is committed to equal opportunity and that is, it seemed to us, what the Southern Community Cohort Study is all about. We are pleased to have the opportunity to support and participate in such an important endeavor to ensure that the burden of cancer and other diseases is reduced for everyone, regardless of race or circumstance."

The SCCS began enrolling participants in spring of 2002, with a total recruitment goal of 105,000 people, two-thirds of them African-American. To date, more than 20,000 participants have been enrolled in Tennessee, Mississippi, Alabama, Georgia, South Carolina, Florida and Kentucky. More than 80 percent are African-American.

Participants are extensively interviewed about their diet, exercise habits and other lifestyle factors that may be involved in disease, and blood and/or saliva samples are being collected. The cohort will be followed for many years, and the various lifestyle and biologic (genetic) factors will be analyzed to determine differences between those that develop (and die from) disease and those that do not.

Such a prospective population-based study is the gold standard when it comes to identifying causes of disease, but to date, the major population-based studies have under-represented African-Americans. This is also the first such study to be conducted in the South.

By necessity, this type of research takes many years; however, private philanthropic support to augment the bare-bones budget provided by the National Cancer Institute will fuel quicker enrollment. That, in turn, will speed epidemiologic analysis and follow-up, the lead investigators say. For more information about the SCCS, visit

Oberhelman, along with Caterpillar Financial Products Division Vice President Jim Beard, recently visited Vanderbilt to officially celebrate the company's pledge. Their visit included meetings with Gee and Jacobson, a tour of the Vanderbilt-Ingram Cancer Center, and lunch with many of the key individuals involved in the SCCS and other work at Vanderbilt-Ingram.

Participants included Orrin Ingram, president and CEO of Ingram Industries Inc. and chair of Vanderbilt-Ingram's Board of Overseers; Dr. Harold Moses, Vanderbilt-Ingram's director; William J. Blot, Ph.D., CEO of IEI and principal investigator of the SCCS; Margaret Hargreaves, Ph.D., associate professor of Internal Medicine at Meharry and co-principal investigator of the SCCS; Tony Scoville, senior vice president of Mastrapasqua Asset Management and member of Vanderbilt-Ingram's board; Dr. Philip Browning, Vanderbilt-Ingram's associate director for Diversity and Minority Clinical Affairs; Jennifer Pietenpol, Ph.D., Vanderbilt-Ingram's associate director for Basic Science Programs.
The Vanderbilt-Ingram Cancer Center, part of Vanderbilt University and Medical Center in Nashville, is the only National Cancer Institute-designated Comprehensive Cancer Center in Tennessee and one of only 39 in the United States. This designation is the highest awarded by the NCI, one of the National Institutes of Health and world's foremost authority on cancer. It recognizes excellence in all aspects of cancer research, the development of innovative new therapies and a demonstrated commitment to the community through education, information and outreach. For more information, visit

Vanderbilt University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to